A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
A master cancer gene hijacks a ‘molecular crowbar’ to make breast cancer cells invasive January 22, 2021
The price of a drug should be based on its therapeutic benefits – not just what the market will bear January 19, 2021
Boehringer Ingelheim Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing November 19, 2019 Boehringer Ingelheim recently presented promising preclinical data from its pan-KRAS program including the novel, oral…